Latest Oncology News

Real-World Implications of the IMpower133 Trial in ES-SCLC

June 28, 2022

Eric S. Nadler, MD of Texas Oncology, discusses the real-world patient characteristics and treatment duration of the immunotherapy combination treatment of the IMpower133 trial in patients with extensive-stage small cell lung cancer.

Overcoming Resistance to ICI Therapy With Ramucirumab and Pembrolizumab in Advanced NSCLC

June 27, 2022

In an interview with Targeted Oncology™, Karen L. Reckamp, MD, discussed that limited options for patients with advanced NSCLC who are resistant to immune checkpoint inhibitor therapy. Reckamp also discusses how Lung-MAP research might play a hand in bringing new therapies in the future.

Chao Discusses Stratifying and Treating Patients With Graft-Vs-Host Disease

June 27, 2022

During a Targeted Oncology case-based roundtable event, Nelson Jen An Chao, MD, discussed risk management and treatment of patients with steroid-refractory acute graft-versus-host-disease as well as chronic graft-versus-host disease.